Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Johnson & Johnson

www.jnj.com

Latest From Johnson & Johnson

Deal Watch: Takeda Signs Broad Cancer Collaboration With Nektar

Takeda will pair five cancer candidates with different mechanisms of action with Nektar's NKTR-214 and Merck follows up its Phase III disappointment verubecestat by licensing a preclinical Alzheimer's drug from Teijen.

Deals M & A

Hospira's Epogen Biosimilar Appears Poised For Quick Advisory Cmte. OK

US FDA will hold its first-ever half-day panel review for a biosimilar; Hopsira's epoetin, which references Amgen's Epogen, has no clinically meaningful differences despite clinical trial conduct issues and PK/PD uncertainty, agency concludes.

Advisory Committees Biosimilars

Sanofi/Regeneron's Kevzara Priced To Break Into A Crowded Market

The partners are looking to create a compelling value proposition for the interleukin-6 inhibitor, approved by FDA to treat moderate to severe RA, by pricing it below the market-leading anti-TNFs.

Immune Disorders Pricing Strategies

Honest's Baby Wipes Recall: A Quality-Control Or Preservatives Problem?

Honest may be finding that its high standards for product quality are hard to meet without traditional preservative workhorses. The company's wipes recall follows a baby powder recall in January, both for potential microbial contamination, which almost inevitably will land Honest on FDA's for-cause inspection list.

Recalls Cosmetic Ingredients
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register